154 related articles for article (PubMed ID: 2575406)
1. Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer.
Manni A; Boucher AE; Demers LM; Harvey HA; Lipton A; Simmonds MA; Bartholomew M
Breast Cancer Res Treat; 1989 Dec; 14(3):289-98. PubMed ID: 2575406
[TBL] [Abstract][Full Text] [Related]
2. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs.
Lamberts SW; Zweens M; Verschoor L; del Pozo E
J Clin Endocrinol Metab; 1986 Jul; 63(1):16-9. PubMed ID: 2872225
[TBL] [Abstract][Full Text] [Related]
3. Serum immunoreactive and bioactive lactogenic hormones in advanced breast cancer patients treated with bromocriptine and octreotide.
Anderson E; Ferguson JE; Morten H; Shalet SM; Robinson EL; Howell A
Eur J Cancer; 1993; 29A(2):209-17. PubMed ID: 8422285
[TBL] [Abstract][Full Text] [Related]
4. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine.
Chiodini PG; Cozzi R; Dallabonzana D; Oppizzi G; Verde G; Petroncini M; Liuzzi A; del Pozo E
J Clin Endocrinol Metab; 1987 Mar; 64(3):447-53. PubMed ID: 2880861
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin analog treatment of acromegaly: new aspects.
Lamberts SW; del Pozo E
Horm Res; 1988; 29(2-3):115-7. PubMed ID: 2900190
[TBL] [Abstract][Full Text] [Related]
6. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly.
Lamberts SW; Zweens M; Klijn JG; van Vroonhoven CC; Stefanko SZ; Del Pozo E
Clin Endocrinol (Oxf); 1986 Aug; 25(2):201-12. PubMed ID: 2878748
[TBL] [Abstract][Full Text] [Related]
7. Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation.
Oppizzi G; Petroncini MM; Dallabonzana D; Cozzi R; Verde G; Chiodini PG; Liuzzi A
J Clin Endocrinol Metab; 1986 Dec; 63(6):1348-53. PubMed ID: 2878007
[TBL] [Abstract][Full Text] [Related]
8. The effect of the somatostatin analog SMS 201-995 on normal growth hormone secretion in the rat. A comparison with the effect of bromocriptine on normal prolactin secretion.
Lamberts SW; Verleun T; Zuiderwijk JM; Oosterom R
Acta Endocrinol (Copenh); 1987 Jun; 115(2):196-202. PubMed ID: 2885995
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
Giusti M; Gussoni G; Cuttica CM; Giordano G
J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
[TBL] [Abstract][Full Text] [Related]
11. Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995.
Barkan AL; Kelch RP; Hopwood NJ; Beitins IZ
J Clin Endocrinol Metab; 1988 Jan; 66(1):16-23. PubMed ID: 2891720
[TBL] [Abstract][Full Text] [Related]
12. Evidence for dopaminergic stimulation of growth velocity in some hypopituitary children.
Huseman CA; Hassing JM
J Clin Endocrinol Metab; 1984 Mar; 58(3):419-25. PubMed ID: 6420440
[TBL] [Abstract][Full Text] [Related]
13. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
Quabbe HJ; Plöckinger U
J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
[TBL] [Abstract][Full Text] [Related]
14. A randomized study of SMS 201-995 versus bromocriptine treatment in acromegaly: clinical and biochemical effects.
Halse J; Harris AG; Kvistborg A; Kjartansson O; Hanssen E; Smiseth O; Djøsland O; Hass G; Jervell J
J Clin Endocrinol Metab; 1990 May; 70(5):1254-61. PubMed ID: 2186055
[TBL] [Abstract][Full Text] [Related]
15. Bromocriptine therapy in acromegaly: use in patients resistant to conventional therapy and effect on serum levels of somatomedin C.
Moses AC; Molitch ME; Sawin CT; Jackson IM; Biller BJ; Furlanetto R; Reichlin S
J Clin Endocrinol Metab; 1981 Oct; 53(4):752-8. PubMed ID: 6793607
[TBL] [Abstract][Full Text] [Related]
16. Suppression of growth hormone and somatomedin C by long-acting somatostatin analog SMS 201-995 in type I diabetes mellitus.
Plewe G; Noelken G; Krause U; Beyer J; del Pozo E
Horm Res; 1987; 27(1):7-12. PubMed ID: 2887504
[TBL] [Abstract][Full Text] [Related]
17. Effect of bromocriptine on serum hormones in acromegaly.
Carlson HE; Levin SR; Braunstein GD; Spencer EM; Wilson SE; Hershman JM
Horm Res; 1984; 19(3):142-52. PubMed ID: 6425186
[TBL] [Abstract][Full Text] [Related]
18. Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.
Ishibashi M; Yamaji T
J Clin Invest; 1984 Jan; 73(1):66-78. PubMed ID: 6140273
[TBL] [Abstract][Full Text] [Related]
19. Prolactin levels and hormonal profile in postmenopausal patients with advanced breast cancer during endocrine treatments.
Pannuti F; Martoni A; Farabegoli G; Piana E
Chemioterapia; 1985 Apr; 4(2):127-34. PubMed ID: 3159487
[TBL] [Abstract][Full Text] [Related]
20. A clinical study of taxotere versus taxotere plus the antiprolactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracyclines.
Lissoni P; Bucovec R; Malugani F; Ardizzoia A; Villa S; Gardani GS; Vaghi M; Tancini G
Anticancer Res; 2002; 22(2B):1131-4. PubMed ID: 12168912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
